Literature DB >> 23472658

IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.

Hayet Rafa1, Houria Saoula, Mourad Belkhelfa, Oussama Medjeber, Imene Soufli, Ryma Toumi, Yvan de Launoit, Olivier Moralès, M'hamed Nakmouche, Nadira Delhem, Chafia Touil-Boukoffa.   

Abstract

Inflammatory bowel diseases (IBDs) are chronic inflammatory diseases of the gastrointestinal tract, which are clinically present as 1 of the 2 disorders, Crohn's disease (CD) or ulcerative colitis (UC) (Rogler 2004). The immune dysregulation in the intestine plays a critical role in the pathogenesis of IBD, involving a wide range of molecules, including cytokines. The aim of this work was to study the involvement of T-helper 17 (Th17) subset in the bowel disease pathogenesis by the nitric oxide (NO) pathway in Algerian patients with IBD. We investigated the correlation between the proinflammatory cytokines [(interleukin (IL)-17, IL-23, and IL-6] and NO production in 2 groups of patients. We analyzed the expression of messenger RNAs (mRNAs) encoding Th17 cytokines, cytokine receptors, and NO synthase 2 (NOS2) in plasma of the patients. In the same way, the expression of p-signal transducer and activator of transcription 3 (STAT3) and NOS2 was measured by immunofluorescence and immunohistochemistry. We also studied NO modulation by proinflammatory cytokines (IL-17A, IL-6, tumor necrosis factor α, or IL-1β) in the presence or absence of all-trans retinoic acid (At RA) in peripheral blood mononuclear cells (PBMCs), monocytes, and in colonic mucosa cultures. Analysis of cytokines, cytokine receptors, and NOS2 transcripts revealed that the levels of mRNA transcripts of the indicated genes are elevated in all IBD groups. Our study shows a significant positive correlation between the NO and IL-17A, IL-23, and IL-6 levels in plasma of the patients with IBD. Interestingly, the correlation is significantly higher in patients with active CD. Our study shows that both p-STAT3 and inducible NOS expression was upregulated in PBMCs and colonic mucosa, especially in patients with active CD. At RA downregulates NO production in the presence of proinflammatory cytokines for the 2 groups of patients. Collectively, our study indicates that the IL-23/IL-17A axis plays a pivotal role in IBD pathogenesis through the NO pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23472658     DOI: 10.1089/jir.2012.0063

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  30 in total

Review 1.  Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases.

Authors:  Imene Soufli; Ryma Toumi; Hayet Rafa; Chafia Touil-Boukoffa
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

2.  Ex vivo immunomodulatory effect of ethanolic extract of propolis during Celiac Disease: involvement of nitric oxide pathway.

Authors:  Oussama Medjeber; Kahina Touri; Hayet Rafa; Zineb Djeraba; Mourad Belkhelfa; Amira Fatima Boutaleb; Amina Arroul-Lammali; Houda Belguendouz; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2018-03-07       Impact factor: 4.473

Review 3.  Treatment of inflammatory bowel disease via green tea polyphenols: possible application and protective approaches.

Authors:  Sajid Ur Rahman; Yu Li; Yingying Huang; Lei Zhu; Shibin Feng; Jinjie Wu; Xichun Wang
Journal:  Inflammopharmacology       Date:  2018-03-12       Impact factor: 4.473

Review 4.  Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia.

Authors:  Monojit Debnath; Michael Berk
Journal:  Mol Neurobiol       Date:  2016-11-29       Impact factor: 5.590

5.  A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome.

Authors:  Sarah Benchabane; Abdelhalim Boudjelida; Ryma Toumi; Houda Belguendouz; Pierre Youinou; Chafia Touil-Boukoffa
Journal:  Int J Immunopathol Pharmacol       Date:  2016-05-19       Impact factor: 3.219

6.  Aberrant up-regulation of iNOS/NO system is correlated with an increased abundance of Foxp3+ cells and reduced effector/memory cell markers expression during colorectal cancer: immunomodulatory effects of cetuximab combined with chemotherapy.

Authors:  Sarra Benkhelifa; Hayet Rafa; Said Belhadef; Hayat Ait-Kaci; Oussama Medjeber; Mourad Belkhelfa; Sabah Hetit; Sonia Ait-Younes; Yvan De Launoit; Olivier Moralès; Hassen Mahfouf; Nadira Delhem; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2019-01-24       Impact factor: 4.473

7.  Unique Regulation of Coupled NaCl Absorption by Inducible Nitric Oxide in a Spontaneous SAMP1/YitFc Mouse Model of Chronic Intestinal Inflammation.

Authors:  Subha Arthur; Balasubramanian Palaniappan; Sheuli Afroz; Uma Sundaram
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

8.  Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung.

Authors:  Paul Ogongo; Liku B Tezera; Amanda Ardain; Shepherd Nhamoyebonde; Duran Ramsuran; Alveera Singh; Abigail Ng'oepe; Farina Karim; Taryn Naidoo; Khadija Khan; Kaylesh J Dullabh; Michael Fehlings; Boon Heng Lee; Alessandra Nardin; Cecilia S Lindestam Arlehamn; Alessandro Sette; Samuel M Behar; Adrie Jc Steyn; Rajhmun Madansein; Henrik N Kløverpris; Paul T Elkington; Alasdair Leslie
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 19.456

9.  Beneficial role of Pistacia lentiscus aqueous extract in experimental colitis: anti-inflammatory and potential therapeutic effects.

Authors:  Insaf-Meriem Boutemine; Manel Amri; Karim Dorgham; Zine-Charaf Amir; Sara Benazzouz; Fahima Ameur; Karim Layaida; Hans Yssel; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2021-06-11       Impact factor: 4.473

Review 10.  The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.

Authors:  Daniele Noviello; Riccardo Mager; Giulia Roda; Riccardo G Borroni; Gionata Fiorino; Stefania Vetrano
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.